Trifarotene: First Approval.

Lesley J Scott

Journal: Drugs 2020;79(17):1905-1909

PMID: 31713811

Abstract

Topical trifarotene (Aklief) is a first-in-class, fourth-generation retinoid [selective retinoic acid receptor (RAR)-γ agonist] being developed by Galderma Research and Development LLC for the treatment of acne vulgaris. In October 2019 trifarotene received its first global approval in the USA for the topical treatment of acne vulgaris in patients 9 years of age and older. This article summarizes the milestones in the development of trifarotene leading to its first global approval for acne vulgaris.

Address: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. [email protected].

DOI: 10.1007/s40265-019-01218-6

Link outs

Free resources

Medical:

https://medlineplus.gov/acne.html

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Subscription / membership required

Full Text Sources:

https://dx.doi.org/10.1007/s40265-019-01218-6

MeSH Terms: Acne Vulgaris, Administration, Topical, Dermatologic Agents, Drug Approval, Humans, Molecular Structure, Receptors, Retinoic Acid, Retinoids, Retinoic Acid Receptor gamma